| Product Code: ETC7741859 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Japan Malignant Pleural Mesothelioma Market Overview |
3.1 Japan Country Macro Economic Indicators |
3.2 Japan Malignant Pleural Mesothelioma Market Revenues & Volume, 2021 & 2031F |
3.3 Japan Malignant Pleural Mesothelioma Market - Industry Life Cycle |
3.4 Japan Malignant Pleural Mesothelioma Market - Porter's Five Forces |
3.5 Japan Malignant Pleural Mesothelioma Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
4 Japan Malignant Pleural Mesothelioma Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about the risks associated with asbestos exposure in Japan |
4.2.2 Advancements in diagnostic technologies for early detection of malignant pleural mesothelioma |
4.2.3 Rising investments in research and development for new treatment options |
4.3 Market Restraints |
4.3.1 Stringent regulations on asbestos use and handling impacting the availability of asbestos-related products |
4.3.2 Limited availability of specialized healthcare professionals for malignant pleural mesothelioma treatment |
4.3.3 High treatment costs and limited insurance coverage for mesothelioma patients in Japan |
5 Japan Malignant Pleural Mesothelioma Market Trends |
6 Japan Malignant Pleural Mesothelioma Market, By Types |
6.1 Japan Malignant Pleural Mesothelioma Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Japan Malignant Pleural Mesothelioma Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Japan Malignant Pleural Mesothelioma Market Revenues & Volume, By Opdivo (Nivolumab), 2021- 2031F |
6.1.4 Japan Malignant Pleural Mesothelioma Market Revenues & Volume, By Yervoy (Ipilimumab), 2021- 2031F |
6.1.5 Japan Malignant Pleural Mesothelioma Market Revenues & Volume, By MTG201, 2021- 2031F |
6.1.6 Japan Malignant Pleural Mesothelioma Market Revenues & Volume, By CBP501, 2021- 2031F |
6.1.7 Japan Malignant Pleural Mesothelioma Market Revenues & Volume, By Lurbinectedin, 2021- 2031F |
7 Japan Malignant Pleural Mesothelioma Market Import-Export Trade Statistics |
7.1 Japan Malignant Pleural Mesothelioma Market Export to Major Countries |
7.2 Japan Malignant Pleural Mesothelioma Market Imports from Major Countries |
8 Japan Malignant Pleural Mesothelioma Market Key Performance Indicators |
8.1 Average survival rates of malignant pleural mesothelioma patients |
8.2 Adoption rate of new diagnostic technologies for mesothelioma detection |
8.3 Number of clinical trials for innovative mesothelioma treatments in Japan |
9 Japan Malignant Pleural Mesothelioma Market - Opportunity Assessment |
9.1 Japan Malignant Pleural Mesothelioma Market Opportunity Assessment, By Drugs, 2021 & 2031F |
10 Japan Malignant Pleural Mesothelioma Market - Competitive Landscape |
10.1 Japan Malignant Pleural Mesothelioma Market Revenue Share, By Companies, 2024 |
10.2 Japan Malignant Pleural Mesothelioma Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |